Immunome
IMNM
104 hedge funds and large institutions have $907M invested in Immunome in 2024 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 29 increasing their positions, 11 reducing their positions, and 11 closing their positions.
427% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 11
294% more capital invested
Capital invested by funds: $230M → $907M (+$677M)
164% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 11
110% more call options, than puts
Call options by funds: $1.71M | Put options by funds: $816K
82% more funds holding
Funds holding: 57 → 104 (+47)
15.68% more ownership
Funds ownership: 50.32% → 66% (+16%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
Top Sellers
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$9.33M |
| 2 |
Renaissance Technologies
New York
|
-$1.54M |
| 3 |
PCM
Prentice Capital Management
Greenwich,
Connecticut
|
-$1.2M |
| 4 |
MC
Mayo Clinic
Rochester,
Minnesota
|
-$1.16M |
| 5 |
Barclays
London,
United Kingdom
|
-$1.08M |
IMNM Hedge Fund Activity: Q1 2024 in Review
104 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q1 2024, worth a combined $907M — up 294% from $230M a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new IMNM positions and 11 closed out — a net gain of 47 holders — while 29 added to existing stakes and 11 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $30.8M. The largest seller was Avidity Partners Management, cutting an estimated $9.33M.
- 104 institutional investors held Immunome (IMNM) as of Q1 2024, up from 57 in Q4 2023.
- Funds reported $907M of Immunome stock for Q1 2024, up 294% quarter-over-quarter.
- 58 funds opened new Immunome positions in Q1 2024 and 11 closed out, a net change of +47 holders.
- The largest Immunome buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $30.8M added.
- The largest Immunome seller in Q1 2024 was Avidity Partners Management, an estimated $9.33M sold.
Based on aggregated 13F filings for Q1 2024.